Last reviewed · How we verify
Natrium chloride
Natrium chloride, marketed by Landstinget i Värmland, is a well-established product in the pharmaceutical market. The key composition patent for Natrium chloride is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk is the loss of market exclusivity post-2028, which could significantly impact revenue.
At a glance
| Generic name | Natrium chloride |
|---|---|
| Sponsor | Landstinget i Värmland |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pericapsular Nerve Group Block Versus Intrathecal Morphine for Analgesia After Total Hip Arthroplasty (NA)
- The Effect of Quadratus Lumborum (QL) Block on the Incidence of Chronic Neuropathic Pain After Retroperitoneal Laparoscopic Donor Nephrectomy: A Study on Neuroinflammation and Neurophysiology (NA)
- Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy (PHASE2)
- Short-term Outcomes of Full Bowel Preparation (MBP+OA) for Colon Cancer Resections Versus no Bowel Preparation (NA)
- The Effects of Carbohydrate-electrolyte Solution on Metabolic Responses in Paediatric Patients (NA)
- Stellate Ganglion Block to Reduce Hot Flushes (NA)
- Pupillometry - Future of Objective Pain Reaction Measurement While Unconscious (NA)
- Contrast-enhanced Bowel Ultrasound in Making a Diagnosis and Follow-up of Patients With Inflammatory Bowel Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |